EPI

Vishay selects AIXTRON SiC multiwafer batch technology

Retrieved on: 
Friday, May 3, 2024
Silicon carbide, Uniformity, Vishay Intertechnology, Senior, VSH, Telecommunications

Vishay is one of the world's largest manufacturers of discrete semiconductors and passive electronic components.

Key Points: 
  • Vishay is one of the world's largest manufacturers of discrete semiconductors and passive electronic components.
  • This, in combination with an excellent uniformity performance on 200mm wafers, has made us choose AIXTRON technology.
  • The AIXTRON team has developed a unique solution for the tightest control of doping levels and uniformity on 200 mm SiC wafers.
  • First introduced in September 2022, AIXTRON’s G10-SiC has quickly become the tool of record for both 150 mm and 200 mm SiC epitaxy.

Pazanga Health Communications Social Media Marketing Work Honored in 2024 American Business Awards®

Retrieved on: 
Wednesday, May 1, 2024
General Health, Social Media, Professional Services, Business, Other Communications, Digital Marketing, Data Analytics, Marketing, Advertising, Content Marketing, Communications, Health, Consulting, Stevie Awards, Patient, Social media, Organization

The collective work submitted included a showcase of the strategy and results for the brand’s organic social media, paid social media marketing campaigns for healthcare practitioners and prospective patients, community engagement, influencer social media marketing, and social-focused content and video development.

Key Points: 
  • The collective work submitted included a showcase of the strategy and results for the brand’s organic social media, paid social media marketing campaigns for healthcare practitioners and prospective patients, community engagement, influencer social media marketing, and social-focused content and video development.
  • “Social media has continued to evolve in the healthcare industry, and for the Pazanga team, it’s become a critical element to many of our clients’ strategies,” said CEO Laura Nobles .
  • “This award is an incredible recognition of the forward-thinking creativity, innovation, and strategy behind the Alpha-Stim social media marketing work, and the power of social media and community engagement in today’s world.”
    The American Business Awards are the U.S.A.’s premier business awards program.
  • “We started 2023 with the goals to increase brand awareness, overall organic social performance, and to drive the sales funnel downward.

WorkForce Software Announces Partner Excellence Award Winners: Accenture, EPI-USE, Intelligenza IT, and SAP SuccessFactors, as Growing Demand for Workforce Management Technology and Global Expansion Continue in 2024

Retrieved on: 
Wednesday, April 24, 2024
Professional Services, Data Management, Apps, Applications, Technology, Human Resources, Software, Workforce, Education, Organization, Public sector, Partner, Investment, Channel partner, Conference, HCM, SAP SuccessFactors, Senior, Mining, SAP, Accenture, Asset management

WorkForce Software , the #1 rated workforce management solution for large employers, announces the winners of its Partner Excellence Awards.

Key Points: 
  • WorkForce Software , the #1 rated workforce management solution for large employers, announces the winners of its Partner Excellence Awards.
  • These exceptional partners were celebrated at WorkForce Software’s VISION 2024 Ignite Conference in Florida's Gold Coast.
  • Regional Software Implementation Partner of the Year: Intelligenza IT is recognized for their dedication to excellence in delivering exceptional WorkForce Software implementations across Latin America.
  • To learn more about WorkForce Software, its market-leading WorkForce Suite solution, and its wide-reaching partner ecosystem , read more here .

EPI Health, LLC Issues Voluntary Recall

Retrieved on: 
Tuesday, April 23, 2024
Health, Pharmaceutical, Online, FDA, Bankruptcy, Chapter Seven, File, Patient, Knowledge, Novin, Food

The EPI Health/Novan Trustee is initiating a voluntary recall of various within-expiry human drug products (Attachment 1) as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products.

Key Points: 
  • The EPI Health/Novan Trustee is initiating a voluntary recall of various within-expiry human drug products (Attachment 1) as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products.
  • EPI Health has not received any reports of adverse events related to this recall.
  • EPI Health, LLC is notifying its distributors and direct consignees by direct mailing and is requesting they further notify their customers/consumers/retailers.
  • Consumers with questions regarding this recall can contact EPI Health at Phone: 888-671-8858 during normal business hours (8am – 5pm CDT) Monday – Friday or thru email at [email protected] .

Piero Cipollone: Innovation, integration and independence: taking the Single Euro Payments Area to the next level

Retrieved on: 
Thursday, April 25, 2024
Reproduction, Failure, Friends, SPAA, Complementarity, Frankfurt, Travel, BIS, Sale, Nature, Market, Council, Investment, Competition, European, European Commission, Disability, USD, Statistics, Visa, Commissioner, ECB, Partnership, Payment, Risk, Policy, Communication, NFC, Apple Pay, Crowding, Safety, Privacy, IOS, Riau rupiah, Digital, SPACE, News, Private sector, Commission, Security, McGuinness, Single market, Public sector, Single Euro Payments Area, Family, Digitalization, Work, European Central Bank, Civil service commission, Opacity, Smartphone, Apple, Central bank, European Parliament, Le Parisien, PSP, BEUC, MIP, SIBS, IDEAL, Cirrus (interbank network), Online shopping

This paper investigates the sensitivity of the demand for safe government debt to currency unhedged and hedged excess returns in a sample of US mutual funds.

Key Points: 
  • This paper investigates the sensitivity of the demand for safe government debt to currency unhedged and hedged excess returns in a sample of US mutual funds.
  • We find evidence of active rebalancing towards government bonds that offer relatively higher returns on an unhedged basis, in particular euro denominated securities.

EQS-News: Epigenomics AG publishes financial results for fiscal year 2023

Retrieved on: 
Wednesday, April 10, 2024
EUR, Supervisory board, AG, Research, Sale, ECX, HGB, Epigenomics AG, Bank statement, News, Investment, Patent, CSO, Commercial code, Lithium

Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.

Key Points: 
  • Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
  • In July 2023, Epigenomics AG entered into an agreement with New Day Diagnostics LLC for the sale of substantially all of its assets, which was approved by the Extraordinary General Meeting in September 2023 and closed in October 2023.
  • Based on the measures taken, Epigenomics AG expects that the available financial resources will be sufficient until 2026.
  • The annual financial statements for the 2023 fiscal year can be found on the Epigenomics website at: https://www.epigenomics.com/news-investors/financial-reports/ .

TurnOnGreen and Endliss Power Team up to Expand Electric Vehicle Charging Infrastructure Across North America

Retrieved on: 
Thursday, March 14, 2024
Other Energy, Automotive, General Automotive, EV, Electric Vehicles, Alternative Energy, Energy, Alternative Vehicles, Fuels, BYD, Partnership, Transport, Multimedia, Renewable energy

The collaboration marks a milestone for the Company as it seeks to expand its networked electric vehicle (“EV”) charging infrastructure across North America, leveraging EPI’s expertise in administering and executing power purchase agreements with commercial clients.

Key Points: 
  • The collaboration marks a milestone for the Company as it seeks to expand its networked electric vehicle (“EV”) charging infrastructure across North America, leveraging EPI’s expertise in administering and executing power purchase agreements with commercial clients.
  • View the full release here: https://www.businesswire.com/news/home/20240314154068/en/
    TurnOnGreen EV Charger with Solar Panel System All copyrights reserved @2024 TurnOnGreen, Inc.
  • Under this partnership, TurnOnGreen and EPI will deliver comprehensive sustainability solutions for installing, operating, and maintaining utility-scale solar power, energy storage systems, and EV charging stations.
  • “We are pleased to partner with Endliss Power to expand our sustainability product portfolio and provide prospective clients with a diverse range of purchasing options for EV charging infrastructure,” said Marcus Charuvastra, President of TurnOnGreen.

Transform Pharmaceutical Authoring Processes With Fonto Integrated Authoring Platform

Retrieved on: 
Wednesday, March 13, 2024
Software, Pharmaceutical, Finance, Health, Artificial Intelligence, Professional Services, Technology, Apps, Applications, Microsoft, Organization, Documentation, Protocol, CMC, Table, Common Technical Document, RWS, IAP, SPL, Trimethadione, Lead

RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, announces the launch of the Fonto Integrated Authoring Platform (IAP), a game-changing solution designed to streamline the document creation and publishing process for the pharmaceutical industry.

Key Points: 
  • RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, announces the launch of the Fonto Integrated Authoring Platform (IAP), a game-changing solution designed to streamline the document creation and publishing process for the pharmaceutical industry.
  • “We’re delighted to announce the availability of Fonto IAP,” explains Jan Benedictus, Managing Director, Fonto.
  • That’s why we’ve introduced Fonto IAP,” according to a Digital Transformation Program Lead at a large pharmaceutical company.
  • Fonto and Tridion are part of RWS’s structured authoring and content management portfolio of solutions.

Koch Industries Recognized as 2024 ENERGY STAR Partner of the Year for Energy Management

Retrieved on: 
Tuesday, March 26, 2024
Natural gas, Environment, Plant, Greenhouse gas, Safety, GHG, Global warming potential, Health, Recognition, HPC, EnergySolutions, Energy management, Heat, Corrosion, Koch Industries, EPA, CO2, Water, Vision, Georgia-Pacific, Renewable energy

"All of us here at Koch are proud to again be named an EPA ENERGY STAR Partner of the Year," said Sheryl Corrigan, Vice President - Environmental, Health and Safety at Koch Industries.

Key Points: 
  • "All of us here at Koch are proud to again be named an EPA ENERGY STAR Partner of the Year," said Sheryl Corrigan, Vice President - Environmental, Health and Safety at Koch Industries.
  • The award recognizes corporate energy management programs that perform at a superior level, demonstrate best practices across the organization and demonstrate companywide energy savings.
  • Leaf River in New Augusta, Mississippi (Georgia-Pacific)
    These projects have been recognized by fellow EPA Partners as reducing energy intensity in business operations.
  • The ENERGY STAR Challenge for Industry is a call to action for industrial sites to reduce their energy intensity by 10% within five years.

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Alnylam Pharmaceuticals, Senior, Enzyme, (glutamate—ammonia-ligase) adenylyltransferase, Doctor of Philosophy, Gene editing, Biotechnology, Roche, Pharmaceutical manufacturing, SAB, Telephone, McGill University, Phosphorylation, Research and development, Growth, DNA, ECO, RNA, Medication, Food, Nucleotide, Element, Administration, Exocrine pancreatic insufficiency, Central Waqf Council, Protein, Net, Small RNA, MBBS, RNA interference, Masad Damha, Video game

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • Including enzyme sales related to PAXLOVID™, total revenues were $26.6 million in fourth quarter 2023 compared to $30.4 million in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product revenues were $18.1 million in fourth quarter 2023 compared to $23.3 million in fourth quarter 2022.
  • Product gross margin, excluding enzyme sales related to PAXLOVID™, was 71% for fourth quarter 2023 compared to 44% in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product gross margin for fourth quarter 2023 was 84% compared to 64% in fourth quarter 2022.